Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Pain. 2018 Feb;159(2):224–238. doi: 10.1097/j.pain.0000000000001106

Figure 3. Fingolimod dose-dependently decreases hyperalgesia before it decreases motor deficits.

Figure 3.

Line graphs describing (A) neuromuscular deficits (B) mechanical sensitivity and (C) cold sensitivity from baseline (BL) through 37 days post-EAE induction with MOG35–55. The 2nd MOG35–55 injection on D2 is not shown. Fingolimod (FTY720) was injected daily (i.p.) from D 15 to 37 (yellow). Histograms describing effect of fingolimod doses on D21 (D, E, F) and D30 (G, H, I). Arrows indicate days of MOG injections. Data represent mean ± SEM from 4–7 mice per drug treatment group. *P<0.05, **P<0.01, ***P<0.001 compared to vehicle controls.